iTAB: Texting to Improve Adherence in HIV+ With Bipolar Disorder

Sponsor
University of California, San Diego (Other)
Overall Status
Completed
CT.gov ID
NCT02090634
Collaborator
(none)
58
1
2
23
2.5

Study Details

Study Description

Brief Summary

Adherence to combination antiretroviral therapy (ART) is critical for successful HIV viral suppression. Nonadherence to ART poses several potentially serious health consequences, including higher viral loads, faster progression to AIDS, and a heightened risk of viral mutations, treatment resistance and HIV transmission.

The prevalence of serious mental illness (SMI) conditions, including bipolar disorder (BD), is elevated among HIV-infected populations and is associated with poor ART adherence. HIV-infected individuals with co-occurring BD (HIV+/BD+), when compared to demographically similar HIV+/BD- persons, demonstrated poorer ART and psychotropic medication adherence and were twice as likely to be non adherent to their ART regimen using a ≥ 90% cutoff score. HIV+/BD+ individuals are particularly at-risk for medication non adherence, and there is a critical need to develop interventions to improve adherence in this population.

Poor psychotropic medication adherence is also common among people with SMI - it has been estimated that 40% of those with BD do not take their mood stabilizer as prescribed. Among persons with BD, nonadherence to psychotropic medications can lead to greater risk for manic and depressive episodes, decreased quality of life, suicide attempts, and hospitalization.

The utilization of mobile health (i.e., mHealth) technologies to improve everyday functioning is growing. mHealth interventions capitalize on technology already incorporated into most people's daily lives (e.g., cell phones) to assist people with behavior modification and disease self-management. Text messaging, in particular, may support daily ART adherence by delivering reminders at precise times to match an individuals' dosing schedule. The initial evidence for using text messaging to improve ART medication adherence has been compelling. Researchers and clinicians have also started employing technology-based approaches to improve treatment for individuals with BD.

Taken together, a distinct need for RCTs utilizing text messaging to improve medication adherence within an at-risk HIV population is warranted. Individualized Texting for Adherence Building (iTAB) is one such intervention.

The investigators propose an intervention development study designed to address these potential mechanisms of nonadherence with the following Specific Aims: 1) To further develop and refine a personalized, automated, real-time, mobile phone, text messaging intervention (iTAB) designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons; 2) To evaluate the acceptability and effectiveness of a brief psychoeducation plus text messaging intervention (iTAB) as compared to psychoeducation alone (CTRL) for the improvement of objectively measured medication adherence among HIV+/BD+ persons; and 3) To examine predictors of within-person trajectories of nonadherence using the longitudinal data collected over the study. In order to realize these aims, the investigators will leverage the infrastructure of two unique UCSD resources increasing likelihood of study success, impact, and innovation: 1) the HIV Neurobehavioral Research Program (HNRP), which encompasses multiple NIH-funded studies that focus on the effects of HIV infection, and 2) the California Institute for Telecommunications and Information Technology (Calit2), which conducts research on state-of-the-art wireless means of health promotion. Initially, the investigators will refine the iTAB intervention to ensure that it is user-centered and tailored to the needs of HIV+/BD+ persons via focus groups and rapid prototyping. Once refined, the proposed iTAB intervention will use text messages that are automated, scalable, personalized, interactive, flexible, and motivating. The investigators will assess the acceptability and effectiveness of iTAB in improving objectively measured adherence (i.e., MEMS caps) over a 4-week period via a pilot RCT with 58 participants were randomized into 2 groups (30 HIV+/BD+ assigned to the iTAB intervention and 28 HIV+/BD+ assigned to a psychoeducational control). Predictors of nonadherence including neuropsychological impairment, and mood will be examined to determine whether iTAB is better able to compensate for these factors associated with nonadherence as compared to CTRL. Further refinement to the iTAB intervention will be made in order to pursue a large-scale R01 using the investigators tailored intervention.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Psychoeducation
  • Behavioral: individualized Texting for Adherence Building (iTAB)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
58 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Texting to Improve Adherence in HIV+ With Bipolar Disorder
Study Start Date :
Apr 1, 2010
Actual Primary Completion Date :
Mar 1, 2012
Actual Study Completion Date :
Mar 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: Personalized Reminder Texting + Psychoeducation (iTAB)

Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a text message that assesses mood. Finally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications.

Behavioral: Psychoeducation
Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.

Behavioral: individualized Texting for Adherence Building (iTAB)
Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.

Active Comparator: Psychoeducation (CTRL)

Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. They will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.

Behavioral: Psychoeducation
Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.

Outcome Measures

Primary Outcome Measures

  1. Proportion Adherent to ARV and Psychotropic Medication by Electronic Monitoring System (MEMS) [4-week]

    MEMS-derived percent adherence to HIV and psychotropic medications over the study period, i.e., ([# of bottle openings]/[# of prescribed doses]*100%).

  2. Dose Timing for ARV and Psychotropic Medications as Determined by Electronic Medication Monitoring System (MEMS). [4-week]

    Medication "dose timing window" for participants was calculated by subtracting the time at which the MEMS cap was opened (i.e., dose taken) from the previously indicated targeted time for dosing (i.e., the time at which participants received adherence text messages for the iTAB intervention group, or time at which participants indicated they would take their medication for the control group). Dose timing windows were used in analyses to indicate the discrepancy between intended dosing time and actual dosing time (in minutes) such that higher values indicate more variable dosing (i.e., decreased therapeutic coverage).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Ability to provide informed consent

  • 18 years or older at the time of enrollment

  • HIV-infected

  • DSM-IV diagnosis Bipolar Disorder

  • Taking at least one medication to treat HIV illness

  • Taking at least one medication to treat bipolar disorder

  • Indication of less than 100% adherence to antiretroviral (ART) medication

  • Willingness to use electronic monitoring caps to track ART medication and BD medication

  • Willingness to respond to text messages

Exclusion Criteria:
  • Axis I psychiatric diagnosis of psychotic spectrum disorder (e.g., schizophrenia)

  • Presence of a neurological condition (beyond HIV infection) known to impact cognitive functioning (e.g., Huntington's Disease, Stroke)

  • Unwillingness or inability to use electronic medication monitoring technology

  • Unwillingness or inability to use daily texting

Contacts and Locations

Locations

Site City State Country Postal Code
1 HIV Neurobehavioral Research Program (HNRP), Department of Psychiatry, Univeristy of California San Diego California United States 92103

Sponsors and Collaborators

  • University of California, San Diego

Investigators

  • Principal Investigator: David J Moore, Ph.D., University of California, San Diego

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
David J. Moore, Ph.D., Associate Professor, University of California, San Diego
ClinicalTrials.gov Identifier:
NCT02090634
Other Study ID Numbers:
  • IDEA Award ID09-SD-047
First Posted:
Mar 18, 2014
Last Update Posted:
Aug 27, 2021
Last Verified:
Aug 1, 2021
Keywords provided by David J. Moore, Ph.D., Associate Professor, University of California, San Diego
Additional relevant MeSH terms:

Study Results

Participant Flow

Recruitment Details HIV+/BD+ participants were recruited from ongoing studies at the UCSD HIV Neurobehavioral Research Program (HNRP).
Pre-assignment Detail 62 participants were assessed for eligibility, and 4 participants were excluded prior to randomization; 2 did not meet study criteria, 2 withdrew. 58 participants were enrolled and randomized into iTAB (n=30) or control group (n=28). 50 participants completed the study and were included in analyses; excluded from analyses were 5 iTAB participants (3 lost MEMS, 2 had adverse events unrelated to study participation) and 3 control participants (1 lost MEMS, 1 lost contact, 1 was deceased).
Arm/Group Title Personalized Reminder Texting + Psychoeducation (iTAB) Psychoeducation (CTRL)
Arm/Group Description Individualized Texting for Adherence Building (iTAB): Participants will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Psychoeducation: Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. Participants will also receive daily text messages to assess mood Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to antiretroviral and psychotropic medications. Participants will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
Period Title: Overall Study
STARTED 30 28
COMPLETED 25 25
NOT COMPLETED 5 3

Baseline Characteristics

Arm/Group Title Personalized Reminder Texting + Psychoeducation (iTAB) Psychoeducation (CTRL) Total
Arm/Group Description The individualized Texting for Adherence Building (iTAB) intervention is designed to improve adherence to antiretroviral and psychotropic medications for HIV+ persons who have bipolar disorder using automated text message reminders. These text messages will be targeted to the specific medication schedule and needs of the individual. Participants will also receive daily text messages to assesses mood. Additionally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to antiretroviral and psychotropic medications. HIV+ persons who have bipolar disorder will receive a one-time psychoeducational intervention reviewing the importance of adherence to antiretroviral and psychotropic medications. Participants will also receive daily text messages to assess mood, but these participants will not receive the medication reminder text messages. Total of all reporting groups
Overall Participants 30 28 58
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]
48.4
(9.2)
45.9
(10.2)
47.1
(9.7)
Sex: Female, Male (Count of Participants)
Female
2
6.7%
4
14.3%
6
10.3%
Male
23
76.7%
21
75%
44
75.9%
Race/Ethnicity, Customized (Count of Participants)
Non-Hispanic White
16
53.3%
11
39.3%
27
46.6%
Non-Hispanic Black
7
23.3%
6
21.4%
13
22.4%
Hispanic
2
6.7%
5
17.9%
7
12.1%
Hispanic Black
0
0%
2
7.1%
2
3.4%
Native American
0
0%
1
3.6%
1
1.7%
Region of Enrollment (participants) [Number]
United States
25
83.3%
25
89.3%
50
86.2%

Outcome Measures

1. Primary Outcome
Title Proportion Adherent to ARV and Psychotropic Medication by Electronic Monitoring System (MEMS)
Description MEMS-derived percent adherence to HIV and psychotropic medications over the study period, i.e., ([# of bottle openings]/[# of prescribed doses]*100%).
Time Frame 4-week

Outcome Measure Data

Analysis Population Description
Of the 30 participants in iTAB intervention group, 25 were analyzed; 3 lost MEMS cap, 1 in rehabilitation facility, 1 too sick.Of the 28 participants in CTRL group, 25 were analyzed; 1 lost MEMS cap, 1 lost to follow up, 1 deceased.
Arm/Group Title Personalized Reminder Texting + Psychoeducation (iTAB) Psychoeducation (CTRL)
Arm/Group Description Individualized Texting for Adherence Building (iTAB): Participants will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Psychoeducation: Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. Participants will also receive daily text messages to assess mood. Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. Participants will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
Measure Participants 25 25
ARV adherence
90.3
90.0
PSY adherence
83.9
90.0
Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Personalized Reminder Texting + Psychoeducation (iTAB), Psychoeducation (CTRL)
Comments We conducted Wilcoxon rank sum (Mann-Whitney) tests in order to examine group (i.e., iTAB vs. CTRL) differences on overall adherence to ARV medications.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.95
Comments Cliff's d = 0.01; calculated to estimate the effect size for between-group comparisons with non-parametric data
Method Wilcoxon (Mann-Whitney)
Comments
Statistical Analysis 2
Statistical Analysis Overview Comparison Group Selection Personalized Reminder Texting + Psychoeducation (iTAB), Psychoeducation (CTRL)
Comments We conducted Wilcoxon rank sum (Mann-Whitney) tests in order to examine group (i.e., iTAB vs. CTRL) differences on overall adherence to PSY medications.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.43
Comments
Method Wilcoxon (Mann-Whitney)
Comments Cliff's d = -0.13; calculated to estimate the effect size for between-group comparisons with non-parametric data
2. Primary Outcome
Title Dose Timing for ARV and Psychotropic Medications as Determined by Electronic Medication Monitoring System (MEMS).
Description Medication "dose timing window" for participants was calculated by subtracting the time at which the MEMS cap was opened (i.e., dose taken) from the previously indicated targeted time for dosing (i.e., the time at which participants received adherence text messages for the iTAB intervention group, or time at which participants indicated they would take their medication for the control group). Dose timing windows were used in analyses to indicate the discrepancy between intended dosing time and actual dosing time (in minutes) such that higher values indicate more variable dosing (i.e., decreased therapeutic coverage).
Time Frame 4-week

Outcome Measure Data

Analysis Population Description
Of the 30 participants in iTAB intervention group, 25 were analyzed; 3 lost MEMS cap, 1 in rehabilitation facility, 1 too sick.Of the 28 participants in CTRL group, 25 were analyzed; 1 lost MEMS cap, 1 lost to follow up, 1 deceased.
Arm/Group Title Personalized Reminder Texting + Psychoeducation (iTAB) Psychoeducation (CTRL)
Arm/Group Description Individualized Texting for Adherence Building (iTAB): Participants will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Psychoeducation: Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. Participants will also receive daily text messages to assess mood. Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. Participants will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
Measure Participants 25 25
Dose timing window for ART
27.8
77.0
Dose timing window for PST
46.8
66.5
Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Personalized Reminder Texting + Psychoeducation (iTAB), Psychoeducation (CTRL)
Comments We conducted Wilcoxon rank sum (Mann-Whitney) tests in order to examine group (i.e., iTAB vs. CTRL) differences on overall dose timing windows for ARV medications.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.02
Comments Cliff's d = 0.37; calculated to estimate the effect size for between-group comparisons with non-parametric data
Method Wilcoxon (Mann-Whitney)
Comments
Statistical Analysis 2
Statistical Analysis Overview Comparison Group Selection Personalized Reminder Texting + Psychoeducation (iTAB), Psychoeducation (CTRL)
Comments We conducted Wilcoxon rank sum (Mann-Whitney) tests in order to examine group (i.e., iTAB vs. CTRL) differences on overall dose timing windows for PSY medications.
Type of Statistical Test Superiority
Comments
Statistical Test of Hypothesis p-Value 0.42
Comments Cliff's d = 0.14; calculated to estimate the effect size for between-group comparisons with non-parametric data
Method Wilcoxon (Mann-Whitney)
Comments

Adverse Events

Time Frame
Adverse Event Reporting Description
Arm/Group Title Personalized Reminder Texting + Psychoeducation (iTAB) Psychoeducation (CTRL)
Arm/Group Description Individualized Texting for Adherence Building (iTAB): Participants will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Psychoeducation: Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. Participants will also receive daily text messages to assess mood. Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. Participants will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
All Cause Mortality
Personalized Reminder Texting + Psychoeducation (iTAB) Psychoeducation (CTRL)
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 0/30 (0%) 1/28 (3.6%)
Serious Adverse Events
Personalized Reminder Texting + Psychoeducation (iTAB) Psychoeducation (CTRL)
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 0/30 (0%) 0/28 (0%)
Other (Not Including Serious) Adverse Events
Personalized Reminder Texting + Psychoeducation (iTAB) Psychoeducation (CTRL)
Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total 2/30 (6.7%) 0/28 (0%)
Immune system disorders
Participant sickness 1/30 (3.3%) 1 0/28 (0%) 0
Social circumstances
Rehabilitation Facility 1/30 (3.3%) 1 0/28 (0%) 0

Limitations/Caveats

1) Small sample size; 2) Short time period; 3) MEMS adherence data based on # of cap openings, not directly whether the medication was ingested; 4) No group without psychoeducation component

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact

Name/Title Dr. David J Moore, Professor of Psychiatry
Organization UCSD HIV Neurobehavioral Research Program (HNRP)
Phone 619-543-5093
Email djmoore@ucsd.edu
Responsible Party:
David J. Moore, Ph.D., Associate Professor, University of California, San Diego
ClinicalTrials.gov Identifier:
NCT02090634
Other Study ID Numbers:
  • IDEA Award ID09-SD-047
First Posted:
Mar 18, 2014
Last Update Posted:
Aug 27, 2021
Last Verified:
Aug 1, 2021